JNJ-39393406

JNJ-39393406 is an experimental small molecule drug developed by Janssen Pharmaceutica (a division of Johnson & Johnson) as a selective positive allosteric modulator of the alpha7 nicotinic acetylcholine receptor. It was investigated for the treatment of depressive disorders and smoking withdrawal. The compound enhances the activity of nicotine and acetylcholine at alpha7 nAChRs by binding to an allosteric site distinct from the agonist-binding site. It does not act on other nicotinic receptor subtypes or serotonin receptors and has minimal off-target activity. Clinical development reached phase II for depressive disorders and smoking withdrawal before being discontinued; it was also previously studied in schizophrenia and Alzheimer's disease[1][2][3][4][6].

Other names

3-(3-((2,2-difluoro-1,3-benzodioxol-5-yl)amino)-5-(4-pyridinyl)-1H-1,2,4-triazol-1-yl)-N,N-dimethylpropanamide953428-73-4T930SOU82PT-930SOU82PT 930SOU82P